Franklin Square Hospital Center

Summary

Franklin Square Hospital Center is a medical facility located in Rosedale, Maryland. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Heart Failure and other specialties. Franklin Square Hospital Center is involved with conducting 92 clinical trials across 144 conditions. There are 4 research doctors associated with this hospital, such as Edward McCarron, Dr. Gary Volkel, MD, Shawna Willey, MD, and Derrick Fox.

Top PIs

Clinical Trials running at Franklin Square Hospital Center

Lung Cancer

Parkinson's disease

Breast Cancer

Colorectal Cancer

Stroke

Cancer

Non-Small Cell Lung Cancer

Bedsores

Hypertrophic Cardiomyopathy

Trigeminal Neuralgia

Pembrolizumab + Chemotherapy

for Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Recruiting

1 award

Phase 1 & 2

8 criteria

Pembrolizumab + Investigational Agents

for Lung Cancer

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Recruiting

1 award

Phase 2

Pembrolizumab + Chemotherapy

for Lung Cancer

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.

Recruiting

1 award

Phase 2

3 criteria